+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study



Dose-Dense Neoadjuvant Chemotherapy plus Radical Surgery in Locally Advanced Cervical Cancer: A Phase II Study



Oncology 89(2): 103-110



To assess the efficacy and toxicity profile of dose-dense cisplatin-based neoadjuvant chemotherapy (NACT) followed by radical surgery in patients affected by locally advanced cervical cancer. Patients affected by carcinoma of the uterine cervix FIGO (International Federation of Obstetrics and Gynecology) stage IB2-IIIB were enrolled into the study. The treatment schedule consisted of 5 cycles of intravenous paclitaxel 60 mg/m(2) plus cisplatin 60 mg/m(2) every 10 days; patients were then submitted to radical hysterectomy and pelvic lymphadenectomy. From January 2011 to March 2013, 22 patients were enrolled. Median age was 47 (26-83) years. FIGO stages included 1 IIA, 15 IIB, 1 IIIA, and 5 IIIB. Ninety-one percent of patients completed all the 5 planned cycles of NACT. Three patients experienced allergic reactions to paclitaxel. Grade 3-4 hematological toxicity was observed in 18% of cases. In 3 cases, grade 3-4 extra-hematological adverse and life-threatening events were reported (1 ototoxicity, 1 transient ischemic attack, and 1 myocardial infarction). No treatment-related death occurred. The operability rate was 86.4%. The overall response rate was 52.6%: 5 patients (26.3%) experienced clinical complete response, and 5 (26.3%) showed a clinical partial response. Stable disease was observed in 47.4% of patients, with no progressive disease recorded. Pathological response was observed in 57.9% of cases. Six out of 19 (31.6%) patients were submitted to adjuvant treatment. Dose-dense cisplatin-based NACT showed a response rate in approximately half of patients. However, in consideration of the reported extra-hematological toxicity, further studies on and new strategies with dose-dense platinum-based NACT are required to improve outcome in cervical cancer patients.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057657764

Download citation: RISBibTeXText

PMID: 25924602

DOI: 10.1159/000381461


Related references

Dose-dense paclitaxel/carboplatin as neo-adjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer: a prospective phase II study. Cancer ChemoTherapy and Pharmacology 83(3): 431-438, 2019

A phase II study: dose-dense carboplatin and paclitaxel as neoadjuvant chemotherapy in locally advanced cervical cancer. Journal of ChemoTherapy 30(4): 247-252, 2018

Phase I-II study of neoadjuvant chemoradiotherapy followed by radical surgery in locally advanced cervical cancer. Anti-Cancer Drugs 12(10): 853-858, 2001

Is aortic lymphadenectomy indicated in locally advanced cervical cancer after neoadjuvant chemotherapy followed by radical surgery? A retrospective study on 261 women. European Journal of Surgical Oncology 42(10): 1512-1518, 2016

Cisplatin with dose-dense paclitaxel before and after radical hysterectomy for locally advanced cervical cancer: a prospective multicenter phase II trial with a dose-finding study. Medical Oncology 34(8): 134, 2017

Safety and Efficacy of Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Radical Surgery Alone in Locally Advanced Cervical Cancer Patients. International Journal of Gynecological Cancer 26(4): 722-728, 2016

Neoadjuvant chemotherapy plus radical surgery followed by chemotherapy in locally advanced cervical cancer. Gynecologic Oncology 125(supp-S1): 0-0, 2012

The role of neoadjuvant chemotherapy followed by radical surgery in the treatment of locally advanced cervical cancer. European Journal of Gynaecological Oncology 24(6): 467-470, 2003

Neoadjuvant chemotherapy prior to radical surgery or radiotherapy for locally advanced cervical cancer. Gynecologic Oncology 52(1): 148, 1994

High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: a preliminary report. Gynecologic Oncology 41(3): 212-216, 1991

Long-term survival following neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. European Journal Of Cancer. 34(3): 341-346,., 1998

Neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer during pregnancy: a case report. American Journal of Obstetrics and Gynecology 197(4): E5-E6, 2007

Ovarian preservation in locally advanced cervical cancer undergoing neoadjuvant chemotherapy and radical surgery. Minerva Ginecologica 70(4): 357-363, 2018

Neoadjuvant chemotherapy and radical surgery in locally advanced cervical carcinoma: a pilot study. Obstetrics and Gynecology 71(3 Pt 1): 344-348, 1988

The long-term efficacy of neoadjuvant chemotherapy followed by radical hysterectomy compared with radical surgery alone or concurrent chemoradiotherapy on locally advanced-stage cervical cancer. International Journal of Gynecological Cancer 21(1): 92-99, 2011